Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 3Phase NA 2Phase 3 1Phase 1 1

Status

Recruiting 2Unknown 1Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 6

Conditions

Multiple Myeloma 95Recurrence 11Neoplasms, Plasma Cell 9Immunoglobulin Light-chain Amyloidosis 6Neoplasms 5Smoldering Multiple Myeloma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Plasmacytoma 2Neoplasm, Residual 2Lymphoma 2Leukemia, Plasma Cell 2Leukemia, Myeloid, Acute 2Leukemia, Lymphocytic, Chronic, B-Cell 2Renal Insufficiency 1Prostatic Neoplasms 1Plasmablastic Lymphoma 1Paraproteinemias 1Non-small Cell Lung Cancer With STK11/LKB1 Mutation 1Myelodysplastic Syndromes 1Microsatellite Unstable Colorectal Cancer 1Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hypergammaglobulinemia 1Disease 1Chromosome 17 deletion 1

Interventions

Dexamethasone 23Melphalan 18Cyclophosphamide 12Filgrastim 10Bortezomib 10Calcium Dobesilate 8Peripheral Blood Stem Cell Transplantation 7daratumumab 6Lenalidomide 6pomalidomide 5dexamethasone acetate 3birtamimab 3Thalidomide 3Radiotherapy 3Interferon-alpha 3Granulocyte Colony-Stimulating Factor 3sargramostim 2isatuximab 2dexamethasone 21-phosphate 2belantamab mafodotin 2Focal Adhesion Protein-Tyrosine Kinases 2Etoposide 2Epoetin Alfa 2Doxycycline 2Busulfan 2siltuximab 1pegfilgrastim 1ixazomib 1fludarabine phosphate 1elotuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Immunoglobulin Light-chain Amyloidosis × daratumumab × Clear all
NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Mayo Clinic

Phase 2 Recruiting
96 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07335887 2026-01-13

Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

Peking University People's Hospital

Phase 2 Not yet recruiting
39 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT07110844 2025-11-19

Teclistamab-Daratumumab in AL Amyloidosis

Columbia University

Phase 2 Recruiting
25 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04304144 2025-03-05

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

Alexion Pharmaceuticals, Inc.

Phase 2 Completed
25 enrolled 14 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04895917 2025-02-20

DarPAL

Fondazione IRCCS Policlinico San Matteo di Pavia

Phase 2 Terminated
27 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04474938 2022-05-10

Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

Peking Union Medical College Hospital

Phase 2 Unknown
40 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡